Ian Ziering: Why My Pregnant Wife Pole Dances

Pregnancy does a body good. Then again, for Ian Ziering‘s expectant wife Erin, so does pole dancing.

The mom-to-be took up the sport following the birth of daughter Mia Loren, 22 months, when she found herself searching for a balance to all things baby.

“I think I got so wrapped up in the motherly world, I was looking for something to make me feel more womanly, more myself,” Erin tells The Bump.

After a night out with her friends, among them a pole dance instructor, the first-time mom — who was already pregnant with the couple’s second child — had her answer.

Courtesy Erin Ziering

“She was telling us that it will make you feel better about your body. It makes you feel more self-aware, and more confident, and that it helps with a lot of issues that happen after you have a baby,” Erin says, adding that while safe, she was still advised to check with her doctor first.

“It’s great exercise. I go once or twice a week, and it’s girl time with my friends. We go out to dinner afterwards,” she shares. “It’s been a great experience, and it kept me in great shape during my pregnancy with a lot of extra energy.”

But she’s not the only one seeing the results of her new talent; Former 90210 actor Ziering is also benefiting from the mama-to-be’s latest moves.

“I had some apprehension for Erin to be involved with that because, um, somehow in my past I’ve seen pole dancing, and I was concerned that a pregnant woman shouldn’t be doing those kinds of things,” he jokes.

Noting that her approach to the pole is “really from the workout perspective,” Ziering admits the pay off has been big in other areas as well. “It helps her get in touch with her sensuality, with her femininity, and with her sexuality, and this is great!” he explains.

“It helps her stay positive when she starts to feel [bad about her body]. Being like, ‘Yeah, I might be pregnant, but I’m making it look good!’ And on top of that, she just gets a little sexier! I think it’s great, and I’m really benefiting.”

With the couple’s second child due in May, Erin is ready for round two of baby bliss, determined to not let the anxiety of life with a newborn deter her from enjoying the experience.

“I felt like with Mia, I was always so nervous about everything, making sure I was doing everything perfectly and reading every book,” she says. “I think this time will be nice because I know what’s going on and I will be more relaxed.”

Ziering and Erin’s own childhoods allows the pair to be the perfect tag-team, although her medical background often tips the scale when it comes to making final decisions.

“We both benefit from growing up in very loving, nurturing environments. We come from similar upbringings,” he says. “Because Erin is a nurse, there’s a lot of credibility to her perspective of raising the baby that I really can’t argue with.”

He continues: “She’ll say, ‘I have looked into this,’ and explain it and I say, ‘Okay! You really have your finger on the heartbeat of child rearing,’ because she does. We go with it.”

Although he cherishes his recent role of a lifetime — dad! — fatherhood comes with its fair share of hardships. “I think the most challenging thing is keeping the stress level down during the times when the baby is inconsolable,” Ziering, 48, admits.

“But I understand that this is all a part of the work, and this is what I signed up for, and that it’s bond-building. I know that the view from the top is worth the climb.”

Joking that life with a toddler has left her less than prepared for the big arrival — “I could be pregnant longer, and it would be okay!” Erin says — she’s anticipating plenty of one-on-one time with baby after the birth.

“Mia will go to school for a couple of hours in the morning, and it will be a nice transition for her,” she explains. “She’ll be able to socialize, learn and be in a safe environment while I’m having bonding time with the new baby. We’re looking forward to that.”

Click here to read the full interview at The Bump.

– Anya Leon

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.

Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.

Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.

"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.

Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.

But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.

National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.

"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.

OPTIONS BULLS TARGET GAINS

The spending cuts, if they go ahead, could hit the defense industry particularly hard.

Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.

Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.

"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.

The stock ended up 0.6 percent at $88.12 on Friday.

If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.

General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.

EYES ON GDP DATA, APPLE

The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.

U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.

Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.

Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.

On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.

(Additional reporting by Doris Frankel; Editing by Kenneth Barry)

Read More..

Egypt parliament election start moved to April 22

CAIRO (Reuters) - Egypt's parliamentary elections, previously scheduled to begin on April 27, have been brought forward to start on April 22, the presidential spokesman said on his Facebook page on Saturday.

Members of Egypt's Coptic Christian minority had criticized the planned timing of the elections because some voting would take place during their Easter holiday.

(Reporting by Alexander Dziadosz; editing by David Stamp)

Read More..

Mandiant goes viral after China hacking report

(Reuters) – Cybersecurity company Mandiant Corp won plaudits from its peers and made front-page news around the world this week when it published a report that purportedly traced a series of cyberattacks on U.S. companies to a Shanghai-based unit of the Chinese army.

But some hackers have turned the tables on the cyber-expert by creating malicious versions of its 74-page report that were infected with computer viruses. They emailed the tainted reports to their victims this week in a bid to wreak havoc under Mandiant’s name.

Though the episode was embarrassing, the company said its systems were not breached. “Mandiant has not been compromised,” the company said on its corporate blog.

Mandiant was founded in 2004 by Kevin Mandia, a former U.S. Air Force cyber-forensics investigator who co-authored an influential textbook on the subject. The company made its name by automating processes used to investigate computer breaches.

Mandiant was largely unknown outside the computer security industry until Monday, when it fingered the People’s Liberation Army’s Shanghai-based Unit 61398 as the most likely driving force behind a Chinese hacking group known as APT1.

China’s Defense Ministry issued a flat denial of the accusations and called them “unprofessional.” But Mandiant won kudos for the unprecedented level of detail in its report, including the location of a building in Shanghai’s Pudong financial hub from which Mandiant said the unit had stolen “hundreds of terabytes of data from at least 141 organizations across a diverse set of industries beginning as early as 2006.”

Other security companies that have published reports on cyberattacks have shied away from so clearly identifying their perpetrators.

“It was a wonderful report,” said Michael Hayden, a former director of the CIA and National Security Agency, who is now with the Chertoff Group. “Everybody is saying ‘it’s about time.’”

The report did not identify the victims of APT1 or Mandiant’s customers, though the company says it has worked for about 40 percent of the Fortune 500.

When asked why he had decided to go public with this report, Mandia, 42, told Reuters, “There is mounting frustration in the private sector. Tolerance is shrinking. We also have a bunch of employees here who are ex-military who sense that frustration and said, ‘Let’s push this out.’”

The report comes ahead of next week’s annual RSA Conference on security in San Francisco, where Mandiant will showcase its products to help companies identify security breaches.

IPO IN THE CARDS?

Mandiant says it begins investigations by installing software it has developed that searches for infections by looking for evidence hackers leave behind. It refers to those digital signatures as Indicators of Compromise, or IOCs.

The proprietary database of those indicators makes up a critical part of the “special sauce” that automates the investigation process and, Mandiant says, enables investigators to root out attackers faster than rivals.

The company has thousands of IOCs in its database, which it is constantly expanding.

“We tend not to take the small jobs. We take the big ones – the ones you would love to read about in the paper, but we keep them out of the paper,” said Mandiant’s chief security officer, Richard Bejtlich.

Some investors have speculated that Mandiant is preparing for an initial public offering in the next year or so. On Friday, it named Mel Wesley to the post of chief financial officer. Wesley was CFO of publicly held OPNET, which was sold to Riverbed Technology in December for about $ 1 billion.

Mandia, who raised $ 70 million by selling stock to Silicon Valley venture capital firm Kleiner Perkins Caufield & Byers and One Equity Partners, the private investment arm of JPMorgan Chase & Co, said he is in no rush to go public. “I do not believe we need more capital,” he said.

Ted Schlein, a partner with Kleiner Perkins, declined to say if an IPO was in the works, but told Reuters: “They are certainly of the size and they certainly have the operating metrics to be a public company.”

Mandia said revenue soared 60 percent last year to about $ 100 million, and he expects it to climb at about the same clip this year on rising demand for Web-based services that help businesses identify when they have been attacked.

The New York Times and News Corp‘s Wall Street Journal recently disclosed that they hired Mandiant to investigate cyberattacks. The company has done similar work for Thomson Reuters Corp, parent of Reuters News, according to two sources with knowledge of the matter. A spokesman for Thomson Reuters declined to confirm it.

PREMIUM FEES

Mandiant declined to discuss its fees, though analysts say they are among the highest in an industry where rivals include much bigger companies such as Accenture, AT&T Inc, Deloitte, PwC and Verizon Communications Inc, which offer cyber-forensics alongside other services.

Mandiant consultants often bill at rates of $ 450 or more an hour, said a person familiar with the company. Teams of consultants investigate breaches for weeks and sometimes several months, typically ringing up bills of between $ 250,000 and $ 1 million.

John Pescatore, director of emerging security trends for the SANS Institute, says Mandiant can charge a premium partly because it gets strong recommendations from the government and other customers.

There is often a waiting list for its services.

“It’s supply and demand. You call Mandiant and Mandiant tells you when they can show up,” said the person familiar with the company, who was not authorized to publicly discuss its finances.

Mandiant also competes against CrowdStrike and Cylance, which are run by the founders of a company known as Foundstone, a pioneer in cyber-forensics that had hired Mandia away from the military. He left Foundstone in 2004 to start Mandiant.

(Reporting by Jim Finkle in Boston; Additional reporting by Joseph Menn in San Francisco and Deborah Charles in Washington; Editing by Tiffany Wu and Prudence Crowther)

Tech News Headlines – Yahoo! News

Title Post: Mandiant goes viral after China hacking report
Url Post: http://www.news.fluser.com/mandiant-goes-viral-after-china-hacking-report/
Link To Post : Mandiant goes viral after China hacking report
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment

Read More..

Diane Lane Signed Divorce Papers from Josh Brolin on Valentine's Day

By Ken Lee

02/22/2013 at 03:00 PM EST

Diane Lane and Josh Brolin

Justin Lubin/NBC/AP

There were likely no flowers or candy exchanged on Feb. 14 between Josh Brolin and soon-to-be ex-wife Diane Lane.

Lane signed her divorce documents on Valentine's Day, documents filed in Los Angeles Superior Court reveal. Lane also cited Feb. 13 as the date of their official separation, although a source tells PEOPLE it was earlier than that.

"They've been separated for several months. This was a hard decision for both of them to make," says a source close to the couple of their split. "The relationship just ran its course."

The pair, who married in a 2004 ceremony at Brolin's central California ranch, were first introduced by the actor's stepmother, Barbra Streisand, at a party in 2002.

Brolin, 45, was recently arrested and held for public intoxication just before midnight on New Year's Eve 2013, but he was released without charge.

Read More..

HP lifts Wall Street, S&P on pace for first weekly loss of year

NEW YORK (Reuters) - Stocks rose on Friday, rebounding off two days of losses as Dow component Hewlett-Packard surged on strong results, but the S&P 500 was on track to end a seven-week-long streak of gains.

The S&P shed 1.9 percent over the previous two sessions, its worst two-day drop since early November, putting the index on pace for its first weekly decline of the year. The retreat was triggered when the Federal Reserve's meeting minutes for January suggested stimulus measures may be halted sooner than thought.

Still, the index is up nearly 6 percent for the year and held the 1,500 support level despite the recent declines, a sign of a positive bias in the market.

"The market is addicted to Fed stimulus and gets withdrawal shakes every time that's threatened, but now we're resuming our course and remain much more attractively valued than other asset classes," said Rex Macey, chief investment officer at Wilmington Trust in Atlanta, Georgia.

Hewlett-Packard Co jumped 9.6 percent to $18.74 as the top boost on both the Dow and S&P 500 after the PC maker's quarterly revenue and forecasts beat expectations. The company cut costs under Chief Executive Meg Whitman's turnaround plan. The S&P technology sector <.splrct> was up 0.8 percent.

The Dow Jones industrial average <.dji> was up 69.41 points, or 0.50 percent, at 13,950.03. The Standard & Poor's 500 Index <.spx> was up 7.74 points, or 0.52 percent, at 1,510.16. The Nasdaq Composite Index <.ixic> was up 18.26 points, or 0.58 percent, at 3,149.75.

For the week, the Dow is off 0.2 percent in its third straight week of slight losses, the S&P is off 0.6 percent and the Nasdaq is off 1.3 percent.

Also buoying tech stocks were gains in semiconductor companies after Marvell Technology Group Ltd forecast results this quarter that were largely above analysts' expectations. Marvell gained market share in the hard-disk drive and flash-storage businesses. The stock rose 2.5 percent to $9.71.

In addition, Texas Instruments Inc raised its dividend by a third and boosted its stock buyback program, lifting shares 5.1 percent to $34.16 while the PHLX semiconductor index <.sox> gained 1.8 percent.

"Dividends growing are another way the market's level is justified, if not especially attractive at these levels," said Macey, who manages about $20 billion in assets.

On the downside, Abercrombie & Fitch dropped 7.6 percent to $45.34 after the clothing retailer reported a drop in fourth-quarter comparable sales, even as its latest quarterly earnings topped estimates.

Insurer American International Group Inc posted fourth-quarter results that beat analysts' expectations. Shares advanced 3 percent to $38.43.

According to Thomson Reuters data through Friday morning, of 439 companies in the S&P 500 that have reported results, 70 percent have exceeded analysts' expectations, compared with a 62 percent average since 1994 and 65 percent over the past four quarters.

Fourth-quarter earnings for S&P 500 companies are estimated to have risen 6 percent, according to the data, above a 1.9 percent forecast at the start of the earnings season.

(Editing by Kenneth Barry)

Read More..

Facebook May Give Older Adults a Mental Boost

Older adults may get a mental boost from using Facebook, early results from a small study suggest.

During the study, 42 adults, ages 68 to 91, who were not familiar with the social networking site were divided into three groups: one group was trained to use Facebook and post once a day; one group was trained to use an online diary site and create short diary entries  visible only to themselves; and one group received no training on either site.

Participants also completed a battery of cognitive  tests before and after their training.

After eight weeks, people in the Facebook group performed 25 percent better than they did at the study’s start on a task that measured their ability to focus on relevant information while a stream of new information is presented — a mental process the researchers refer to as “updating.” People in the other two groups didn’t improve in their updating ability.

However, both the Facebook group and the online diary group showed improvements in how quickly they were able to process information compared to the group that did not learn to use a new site.

“To me this suggests that just learning and using one of these two websites provided a boost for how quickly people process information,” said study researcher Janelle Wohltmann, a graduate student in the University of Arizona department of psychology.

The findings are preliminary, and Wohltmann is still analyzing the results to determine if there are any more differences between the groups. Larger studies will also need to be conducted to confirm the results.

Wohltmann hopes to find out why Facebook, but not the online diary site, improved people’s updating ability.

She speculates that Facebook’s format, which shows updates from both the user and his or her friends, may play a role.

“In these ‘mental updating’ tasks, participants are being asked to continuously focus on only the most relevant information, and to forget other pieces of information as they become irrelevant.  When you view the news feed in Facebook, new information is continuously popping up from your Facebook friends,” while the online diary site only shows new information that you write, Wohltmann said. “I wonder if perhaps the fact that you are constantly filtering through new pieces of information while viewing Facebook may have something to do with it,” she added.

For people who don’t want to join Facebook, other tasks may have similar effects on brain function, Wohltmann said.

Studies suggest that “staying mentally, physically and socially active in older age helps maintain or boost cognitive function,” Wohltmann said. Learning new activities, volunteering or exercising are some ways to stay active, she noted.

The findings were presented this month at the annual meeting of the International Neuropsychological Society in Hawaii.

Pass it on: Older adults who were trained to use Facebook saw improvements in some aspects of their cognitive function, a new study finds.

Follow MyHealthNewsDaily on Twitter @MyHealth_MHND.  Findus on Facebook.

Copyright 2013 MyHealthNewsDaily, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Social Media News Headlines – Yahoo! News

Title Post: Facebook May Give Older Adults a Mental Boost
Url Post: http://www.news.fluser.com/facebook-may-give-older-adults-a-mental-boost/
Link To Post : Facebook May Give Older Adults a Mental Boost
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment

Read More..

Diem Brown Blogs: Farewell for Now

By Diem Brown

02/21/2013 at 04:00 PM EST

In her PEOPLE.com blog, Diem Brown, the Real World/Road Rules Challenge contestant recently diagnosed with ovarian cancer for the second time, opens up about her desire for a child and the ups and downs of cancer and fertility procedures.

First and foremost, I feel so blessed to have been able to share my crazy journey and hear your personal experiences on this PEOPLE.com blog.

Although I won't be posting a blog as often going forward, I am so excited to be able to keep writing and posting blogs here when big things happen in my life and/or when I hear or see something that I think y'all would love to start a conversation about. Please Tweet me at @DiemBrown if you ever have any suggestions or think of a topic that you would like to throw out there!

For instance, I am so curious about Eastern medicine as an addition to the Western medicine regime, so after I give it a real go I would love to share what I learn from it.

I also have I say I am beyond excited about Robin Roberts' return to Good Morning America! She is a true example of a lioness heart. ... She was able to envision her goal of returning to GMA even through all the hardships she endured. Robin had a goal and she invited the world to watch her as she set out to conquer her battle while keeping her goal in mind.

Watching Robin say "Good morning, America," made me instantly smile as you could feel the elated emotion shine from her eyes as she spoke.

We need these sorts of stories to be shared and we need to see that there are real life happy endings. The world is full of hardships and when you are stuck in that dark place you yearn to grab onto any sort of light that can help you see there is hope.

Hope is one of the strongest emotions and hope can overcome fear and despair ... if hope is given enough fuel. So thank you, Robin Roberts, for fueling that hope flame for so many of us fighting our own battles. You have shown that goals can be reached with time by never letting the word quit seep into your mindset.

Congratulations Robin and we are all look forward to continue hearing you say, "Good morning, America," every day.

Read More..

Flu shot did poor job against worst bug in seniors

ATLANTA (AP) — For those 65 and older, this season's flu shot is only 9 percent effective against the most common and dangerous flu bug, according to a startling new government report.

Flu vaccine tends to protect younger people better than older ones and never works as well as other kinds of vaccines. But experts say the preliminary results for seniors are disappointing and highlight the need for a better vaccine.

For all age groups, the vaccine's effectiveness is moderate at 56 percent, which is nearly as well as other flu seasons, the Centers for Disease Control and Prevention said Thursday.

For those 65 and older, it is 27 percent effective against the three strains in the vaccine, the lowest in about a decade but not far below from what's expected. But the vaccine did a particularly poor job of protecting older people against the harshest flu strain, which is causing most of the illnesses this year. CDC officials say it's not clear why.

Vaccinations are now recommended for anyone over 6 months, and health officials stress that some vaccine protection is better than none at all. While it's likely that older people who were vaccinated are still getting sick, many of them may be getting less severe symptoms.

"Year in and year out, the vaccine is the best protection we have," said CDC flu expert Dr. Joseph Bresee.

To be sure, the preliminary data for seniors is less than definitive. It is based on fewer than 300 people scattered among five states.

But it will no doubt surprise many people that the effectiveness is that low, said Michael Osterholm, a University of Minnesota infectious disease expert who has tried to draw attention to the need for a more effective flu vaccine.

Among infectious diseases, flu is considered one of the nation's leading killers. On average, about 24,000 Americans die each flu season, according to the CDC.

This flu season started in early December, a month earlier than usual, and peaked by the end of year. Older people are most vulnerable to flu and its complications, and the nation has seen some of the highest hospitalization rates for people 65 and older in a decade.

Flu viruses tend to mutate more quickly than others, and it's not unusual for multiple strains to be spreading at the same time. A new vaccine is formulated each year targeting the three strains expected to be the major threats. But that involves guesswork.

Because of these challenges, scientists tend to set a lower bar for flu vaccine. While childhood vaccines against diseases like measles are expected to be 90 or 95 percent effective, a flu vaccine that's 60 to 70 percent effective in the U.S. is considered pretty good.

By that standard, this year's vaccine is OK. The 56 percent effectiveness figure means people have a 56 percent lower chance of winding up at the doctor for treatment of flu symptoms.

For seniors, a flu vaccine is considered pretty good if it's in the 30 to 40 percent range, said Dr. Arnold Monto, a University of Michigan flu expert.

Older people have weaker immune systems that don't respond as well to flu shots. That's why a high-dose version was recently made available for those 65 and older. The new study was too small to show whether that made a difference this year.

The CDC estimates are based on about 2,700 people who got sick in December and January. The researchers traced back to see who had gotten flu shots and who hadn't. An earlier study put the vaccine's overall effectiveness slightly higher, at 62 percent.

The CDC's Bresee said there's a danger in providing preliminary results because it may result in people doubting — or skipping — flu shots. But the data was released to warn older people who got shots that they may still get sick and shouldn't ignore any serious flu-like symptoms, he said.

The new data highlights an evolution in how experts are evaluating flu vaccine effectiveness. For years, it was believed that if the viruses in the vaccine matched the ones spreading around the country, then the vaccine would be effective. This year's shot was a good match to the bugs going around this winter, including the harsher H3N2 that tends to make people sicker.

But the season proved to be a moderately severe one, with many illnesses occurring in people who'd been vaccinated.

____

Online:

CDC report: http://www.cdc.gov/mmwr

Read More..